Ertugliflozin (ERTU), a SGLT2 inhibitor, improves glycemic control in adults with T2DM. T2DM is prevalent among adults of Hispanic ethnicity in the U.S. Here we report a post hoc analysis of ERTU efficacy and safety in Hispanic/Latino pts in the ERTU Phase 3 program. A1C, body weight (BW), and systolic blood pressure (SBP) were evaluated with ERTU 5 and 15 mg (vs. placebo [PBO] or glimepiride [GLIM]) and ERTU with sitagliptin 100 mg (ERTU 5 or 15 mg/SITA vs. PBO or SITA). Adverse events (AEs) were evaluated.
Among 4855 pts, baseline characteristics were generally similar across treatment groups and between the group of pts self-reported as Hispanic/Latino (n=1178, 24.3%) and the non-Hispanic/Latino group. No meaningful differences were observed between these ethnic groups in A1C reductions with ERTU 5 and 15 mg at week 26 in a pooled analysis of PBO-controlled studies, at week 52 in a GLIM-controlled study, or with ERTU 5 mg/SITA and ERTU 15 mg/SITA groups at week 26 in PBO- and SITA-controlled studies (Figure). Similarly, no meaningful differences between ethnic groups were observed in BW and SBP reductions with ERTU 5 and 15 mg across the program. ERTU was generally well tolerated. The incidence of AEs was similar between ethnic groups. ERTU efficacy and safety were similar between Hispanic/Latino and non-Hispanic/Latino groups. NCTs: 01958671, 02033889, 02036515, 01999218, 02226003, 02099110, 01986855.
J. Liu: Employee; Self; Merck & Co., Inc. L. Tarasenko: Employee; Self; Pfizer Inc. M.C. Ellison: Employee; Self; Merck & Co., Inc. A. Pong: None. S. Huyck: Employee; Self; Merck & Co., Inc. J.P. Mancuso: Employee; Self; Pfizer Inc. Employee; Spouse/Partner; Pfizer Inc. Stock/Shareholder; Spouse/Partner; Pfizer Inc. Stock/Shareholder; Self; Pfizer Inc. S.G. Terra: Employee; Self; Pfizer Inc. I. Gantz: Employee; Self; Merck & Co., Inc.
Merck Sharp & Dohme Corp; Pfizer Inc.
